Analysis of Expression of Programmed Cell Death 1 Ligand 1 (PD-L1) in Malignant Pleural Mesothelioma (MPM)

• Susana Cedrés ,

  * E-mail: scedres@vhebron.net

  Affiliation Medical Oncology Service/Vall d´Hebron Institute Oncology, Vall d’Hebron University Hospital, Barcelona, Spain

  ⨯
• Santiago Ponce-Aix,

  Affiliation Medical Oncology Service/ 12 de Octubre University Hospital, Madrid, Spain

  ⨯
• Jon Zugazagoitia,

  Affiliation Medical Oncology Service/ 12 de Octubre University Hospital, Madrid, Spain

  ⨯
• Irene Sansano,

  Affiliation Pathology Department/ Vall d’Hebron University Hospital, Barcelona, Spain

  ⨯
• Ana Enguita,

  Affiliation Pathology Department/12 de Octubre University Hospital, Madrid, Spain

  ⨯
• Alejandro Navarro-Mendivil,

  Affiliation Medical Oncology Service/Vall d´Hebron Institute Oncology, Vall d’Hebron University Hospital, Barcelona, Spain

  ⨯
• Alex Martinez-Marti,

  Affiliation Medical Oncology Service/Vall d´Hebron Institute Oncology, Vall d’Hebron University Hospital, Barcelona, Spain

  ⨯
• Pablo Martinez,

  Affiliation Medical Oncology Service/Vall d´Hebron Institute Oncology, Vall d’Hebron University Hospital, Barcelona, Spain

  ⨯
• Enriqueta Felip

  Affiliation Medical Oncology Service/Vall d´Hebron Institute Oncology, Vall d’Hebron University Hospital, Barcelona, Spain

  ⨯